NEW INSIGHTS IN THE DIAGNOSIS AND TREATMENT OF HEART FAILURE

Yakupboev Sherzod Ergashboy o'g'li
Student of Tashkent Pediatric Medical institute

Heart failure is a complex and debilitating condition that continues to be a significant burden on healthcare systems worldwide. This introduction sets the stage for the subsequent exploration of new insights in the diagnosis and treatment of heart failure. We will delve into the latest advancements in our understanding of the pathophysiology of heart failure, the evolving diagnostic tools and techniques, and the cutting-edge therapeutic options that are reshaping the management of this condition. By addressing these key areas, we aim to provide a comprehensive overview of the current landscape in the field of heart failure, offering valuable knowledge and perspectives for healthcare professionals and researchers. This discussion of new insights is essential for enhancing patient outcomes, improving quality of life, and ultimately reducing the global impact of heart failure.

We will explore the pathophysiology of heart failure, delving into the intricate mechanisms that underlie the development and progression of the condition. This will involve a detailed examination of the physiological and structural changes that occur in the heart, as well as the compensatory mechanisms that are activated in response to cardiac dysfunction. Overall, this section will lay the foundation for our subsequent discussions on the application of proteomics in understanding heart failure, providing a comprehensive framework for our exploration of this critical topic.

Following this, we will examine the etiology of heart failure, exploring the diverse range of factors that can contribute to the development of the condition. This will encompass an in-depth analysis of the various potential causes, including coronary artery disease, hypertension, valvular heart disease, and other precipitating factors. We will also discuss the role of comorbidities in exacerbating heart failure and the impact of risk factors such as smoking, obesity, and sedentary lifestyle.

Firstly, we will delve into the definition and prevalence of heart failure, providing a comprehensive understanding of the condition and its impact on global health. This will include an exploration of the various classifications and stages of heart failure, as well as an overview of its epidemiology and the current burden it places on healthcare systems.

Heart failure is a complex and debilitating condition that affects millions of people worldwide. In this section, we will provide an overview of the key aspects of heart failure, including its definition, prevalence, etiology, and pathophysiology.

The prevalence of heart failure is on the rise, with an estimated 6.2 million adults in the United States living with the condition. It is a leading cause of hospitalization in people aged 65 and older, and its prevalence is expected to increase as the population ages. Heart failure also carries a significant economic burden, with annual healthcare costs reaching billions of dollars. In addition, the condition is associated with a high mortality rate, with approximately 50% of individuals diagnosed with heart failure dying within 5 years. Understanding the definition and prevalence of heart failure is crucial in order to develop effective strategies for prevention, diagnosis, and management of this debilitating condition.

Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood to meet the body's needs for oxygen and nutrients. It can affect the left or right side of the heart, or both. Left-sided heart failure occurs when the left ventricle cannot pump blood effectively to the rest of the body, leading to a buildup of fluid in the lungs. Right-sided heart failure occurs when the right ventricle cannot effectively pump blood to the lungs,

In summary, a comprehensive understanding of the etiology and pathophysiology of heart failure is essential in addressing the underlying causes and mechanisms driving the progression of this debilitating condition. Through the application of proteomics, researchers can unravel the intricate molecular pathways and protein interactions underlying heart failure, paving the way for the development of novel diagnostic biomarkers and innovative therapeutic strategies to combat this global health burden.

Pathophysiologically, heart failure manifests as a maladaptive response to the initial insult, involving impaired myocardial function, altered neurohormonal regulation, and progressive remodeling of the heart. This dysfunctional interplay of neurohormonal activation, impaired contractility, and structural changes ultimately leads to the clinical syndrome of heart failure, characterized by symptoms such as dyspnea, fatigue, and fluid retention. Understanding the intricate interplay of these etiological and pathophysiological factors is crucial in guiding targeted therapeutic interventions and improving the management of heart failure.

Heart failure is a complex and multifactorial condition that arises from various etiologies and pathophysiological mechanisms. Etiologically, heart failure can result from underlying cardiovascular diseases such as coronary artery disease, hypertension, and myocardial infarction. Other contributing factors include valvular heart disease, cardiomyopathies, and congenital heart defects. Additionally, non-cardiac conditions like diabetes, obesity, and chronic kidney disease can also precipitate heart failure through their impact on the cardiovascular system.

A number of innovative approaches are being investigated on the basis of improved survival and quality of life in patients refractory to medical therapy and

excluded from cardiac transplantation lists. These procedures include the optimization of medical therapy, coronary artery bypass surgery and valve surgery in high risk patients, ventricular restoration techniques, and the implantation of ventricular assist devices as destination therapy or other approaches (such as cardiac resynchronization therapy) [1]. Future therapies for heart failure could include new approaches with stem cell therapy, associated with standard revascularization techniques or with other procedures such as the implantation of innovative ventricular assist devices, new ventricular restoration techniques, or new drugs. The continuous innovations in proteomic technologies will help pinpoint protein posttranslational modifications that could help elucidate the transition to heart failure (HF). This link between biology and technology could greatly assist in identifying biomarkers with increased specificity as well as more effective therapies.

The Contribution of Proteomics to Our Understanding of Biological Systems. Nowadays, mass spectrometry (MS) is used to detect, identify, and quantify a wide array of compounds spanning from small molecules, pharmaceuticals, metabolites (hence metabolomics), lipids (hence lipidomics), and peptides and proteins (hence peptidomics and proteomics). In the last four, the "-omics" suffix implies that hundreds to thousands of compounds can be detected in a single analysis providing a snapshot of a given metabolome, lipidome, peptidome, or proteome, respectively. As it is easy to imagine this capability has enhanced tremendously our understanding of biological systems. For the sake of brevity we will address the contribution of proteomics to HF research in this section. For the same reason we cannot be exhaustive and defer to other comprehensive reviews on cardiovascular proteomics for the interested reader [2]. The proteome was first defined publicly a little over a decade ago as the "protein complement of the genome" or the protein make-up that can be identified and quantified from a given biological sample. As an axiom, proteomics is the complex of technologies (centered around MS) used to study the proteome. Perhaps the most important contribution of these technologies to modern medicine is the discovery of the dazzling diversity of protein posttranslational modifications (PTMs). There are over 400 PTMs, such as phosphorylation, nitrosylation, acetylation, and methylation, currently listed in protein databases [3]. The vast majority of PTMs have an effect on a protein's life may it be activity, localization, turnover, and so forth or in other words its function. Posttranslational modifications are the most likely integrators of the interactions between the phenotype and the environment due to their dynamic regulation and this new knowledge has profound implications for biomedicine. For instance, the sporadic nature of many diseases, such as HF, could be explained in the light of proteins and their PTMs rather than the genetic background. In fact, the prediction of a phenotype solely based on genes is inherently complicated by the exponential increase in complexity when moving genes through transcripts to modified

proteins and their complexes. The realization that PTMs are so abundant in nature is daunting; however, the technological advances seen in the last decade let us hope that their mapping is within reach and that with this information we will have a high-resolution picture of the molecular phenotype of many diseases in the near future. As technologies quickly develop, their potential clinical applications also multiply. Like the computer industry some of these technologies, and mainly MS, have now reached a point where performance has allowed targeting an intermediate segment of the users market. That is to say that highperformance MS instruments which were previously relegated to well-funded and highly specialized research groups are now slowly becoming accessible to smaller institutions, including hospitals and clinical labs. The great potentials for biomarkers discovery and clinical labs analyses are still largely unmet by the limited knowledge of the scientific and medical communities.

The number of methodological approaches that have arisen in the last decade is also complex. They can be broadly divided into protein- and peptidecentric (or top-down and bottom-up to use a widespread nomenclature, resp.). The most common approaches are peptide-centric, which means that proteins are digested into peptides prior to MS analysis due to the increased stability of the latters and the fact that they can be measured more accurately.The separation of proteins prior to MS analysis can be achieved by polyacrylamide gel electrophoresis (PAGE) or LC (hence gel-based and gel-free approaches); however, LC is also used to inject proteins and peptides directly in the MS. Moreover, other separation techniques such as capillary electrophoresis (CE) can be also utilized [4].

One of the typical approaches based on the direct LC-MS analysis of digested proteomes is commonly known as “shotgun” [5], as peptides are digested, desalted, and injected into the MS. When it comes to quantification, two different schools of thought advocate for label and label-free approaches. In the former, peptides are chemically derived with various chemical “tags” prior to MS analysis. These are released in the MS to work as “reporters” for the quantity of a given peptide (and therefore protein) [6]. However, due to the increased reproducibility of separation and MS technologies, it is now possible to have an accurate quantification also in absence of reporters (label-free) [4]. Finally, the clinical relevance of top-down or protein-centric proteomics in HF research is also rapidly emerging [7].

Peptide-centric approaches can be utilized for both the “entire” proteome (proteome-wide) or fractions of it (subproteomes). Indeed the complexity of biological systems is such that it is hard to predict when full proteome-wide coverage will be achieved for complex samples. The detection of peptides in a MS is a competitive process; therefore the higher the complexity of the sample, the higher the chance that low-abundant peptides (proteins) may be missed. For this reason, the enrichment of

specific PTMs (e.g., phosphoproteome [6]) or subproteomes (e.g., different organelles [8]) greatly enhances sensitivity.

Targeted proteomics or the application of these technologies BioMed Research International 3 to highly enriched subproteomes (e.g., individual proteins end, their PTMs, and their complexes) is arguably the best approach to gain the deepest level of detail. A successful example of this concept is the crossover of a MS technique known as multiple reaction monitoring (MRM) from the pharmaceutical industry to proteomics. Briefly MRM allows to precisely quantify proteins using the quantity of few peptide fragments in a tandem MS. The use of isotopically labeled internal standard enables absolute quantification. As an example, multiple reaction monitoring was recently used to accurately quantify the phosphorylation sites (known and new) of cardiac TnI, one of the gold standard markers to diagnose cardiac ischemia [9].

Proteomics to Tackle Emerging Concepts in HF Research. There has been an increasing consensus on the similarities between well-established organ proteinopathies (such as Alzheimer's and Parkinson's diseases) and HF [10]. This concept was pioneered a little over ten years ago by Robbins and colleagues who reported the presence of preamyloid oligomers (PAOs) similar to those observed in the brains of Alzheimer's patients, in cardiac specimens from HF patients [11]. In the last few years, this concept has been revamped by several studies. Few of the most recent ones have conveniently exploited proteomic technologies [12–14]. Indeed, it is not surprising that proteomic analysis will assist with elucidating new mechanisms of proteotoxicity as they happen not only in the brain but also in other organs, such as the heart. Of particular interest is the role of protein PTMs [15, 16]. These can be placed both enzymatically (such as phosphorylation) or occur as the result of environmental stress (such as oxidation). The latters are not regulated and therefore they can accumulate in a pathological fashion [12, 15].

The modern approach to the diagnosis and treatment of heart failure is multidisciplinary and should be based on a close collaboration among researchers, clinicians, and cardiac surgeons, particularly given that mandatory multiorgan attention is required in these high risk patients. Future therapies for heart failure could include ventricular assist devices implantation or ventricular restoration techniques with the aim to obtain a reverse, positive remodeling in the unloaded heart. With an expanding "toolbox" of comprehensive basic, medical, surgical and technological approaches, it is expected that these novel findings will soon be translated to the clinical practice. In fact, new therapeutic strategies are desperately needed by the millions of patients suffering from heart failure

REFERENCES

[1] F. Nicolini and T. Gherli, “Alternatives to transplantation in the surgical therapy for heart failure,” European Journal of CardioThoracic Surgery, vol. 35, no. 2, pp. 214–228, 2009.

[2] G. Agnetti, C. Husberg, and J. E. van Eyk, “Divide and Conquer: the application of organelle proteomics to heart failure,” Circulation Research, vol. 108, no. 4, pp. 512–526, 2011.

[3] P. Randell, “It’s a MALDI but it’s a goodie: Maldi-Tof mass spectrometry for microbial identification,” Thorax, vol. 69, no. 8, pp. 776–778, 2014.

[4] M. A. Schechter, M. K. H. Hsieh, L. W. Njoroge et al., “Phosphoproteomic profiling of human myocardial tissues distinguishes ischemic from non-ischemic end stage heart failure,” PLoS ONE, vol. 9, no. 8, Article ID e104157, 2014.

[5] E. Hammer, M. Goritzka, S. Ameling et al., “Characterization of the human myocardial proteome in inflammatory dilatedbcardiomyopathy by label-free quantitative shotgun proteomics of heart biopsies,” Journal of Proteome Research, vol. 10, no. 5, pp. 2161–2171, 2011.

[6] Z. Su, H. Zhu, M. Zhang et al., “Salt-induced changes in cardiac phosphoproteome in a rat model of chronic renal failure,” PLoS ONE, vol. 9, no. 6, Article ID e100331, 2014.

[7] G. Agnetti, “Modified troponin I as a candidate marker forchronic heart failure: a top-down perspective,” Circulation:Cardiovascular Genetics, vol. 4, no. 5, pp. 579–580, 2011.

[8] G. Agnetti, N. Kaludercic, L. A. Kane et al., “Modulation of mitochondrial proteome and improved mitochondrial function by biventricular pacing of dyssynchronous failing hearts,” Circulation: Cardiovascular Genetics, vol. 3, no. 1, pp. 78–87, 2010.

[9] P. Zhang, J. A. Kirk, W. Ji et al., “Multiple reaction monitoring to identify site-specific troponin i phosphorylated residues in the failing human heart,” Circulation, vol. 126, no. 15, pp. 1828–1837, 2012.

[10] M. S. Willis and C. Patterson, “Proteotoxicity and cardiac dysfunction—Alzheimer’s disease of the heart?” The New England Journal of Medicine, vol. 368, no. 5, pp. 455–464, 2013.

[11] A. Sanbe, H. Osinska, J. E. Saffitz et al., “Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis,” Proceedings of the National Academy of Sciences of the Un